Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT03439449 |
Other study ID # |
KI-CLEOS-CPDS |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
May 1, 2017 |
Est. completion date |
December 31, 2024 |
Study information
Verified date |
February 2023 |
Source |
Karolinska Institutet |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The aim is to determine the additional value of computerized, patient-entered medical
histories for the management of patients presenting at the emergency department with chest
pain.
Description:
The purpose of this study is to determine the value of a detailed medical history, acquired
by computer-directed, patient self-entry of data, for efficient disposition of patients
presenting to the emergency department (ED) with chest pain and non-diagnostic first ECG
and/or serum markers for acute coronary syndrome (ACS). The research questions posed are:
will the added data and systems-based analysis of the data provided by computerization of
these processes, as compared with routine physician-acquired histories and analysis; (1)
safely risk stratify patients with chest pain, and (2) save time and resources?
Computerized, patient-entered histories will be collected with the software program CLEOS
running on tablets (iPad®, Apple Inc, Cupertino, California, USA). The histories to be
collected include demographic data, present illness, systems review, past medical history,
prescription drugs, previous adverse drug reactions, social history, life-style risks, and
family history. Histories will be collected during wait times in the ED, e.g., before
patients are seen by a physician and while patients wait for reports of laboratory data
collected by routine care.
Data acquired by CLEOS will be related to clinical outcomes in the acute setting and at 30
days and 1 year post-presentation for patients without documented ACS in the acute setting.
Outcomes for all patients will be extracted from hospital records and national registries.
For the validation and future development of CLEOS, interviews with patients for the
evaluation of patient experience regarding feasibility, acceptance, comprehensiveness and
technical aspects of answering the CLEOS interview will take place within one to three months
after the ED visit.
This is an exploratory study in which the calculation of the number of participating patients
is based on the desired precision of sensitivity and specificity. Assuming that the
prevalence is 0.5 (50 %), a power calculation with nQuery® version 7.0 (Statistical Solutions
Ltd, Boston, Massachusetts, USA) shows that with 1000 patients the estimated precision of
sensitivity and specificity is ±0.03 (3 %). The more the extreme the result, i.e. sensitivity
or specificity approaching 0 or 1 (100 %), the higher the precision. The models will be
developed in the first 50% of the data acquired (training data set) and validated in the last
50% of the data acquired (validation data set). We also intend to make estimates in
subgroups. To ascertain that such estimates can be done, an even larger number of patients
must be recruited. Thus, the study intends to recruit data from approximately 2000 patients.
Taken together, this study:
1. will evaluate established clinical guidelines risk scores, as populated with CLEOS data,
and compare these results with data obtained during the concurrent ED visit and made
available in the standard hospital medical records;
2. will assess how data collected with CLEOS in combination with established risk scores
can rule-in and rule-out a diagnosis of an ACS, we will calculate sensitivity,
specificity and negative and positive predictive value;
3. aim to develop new risk prediction scores for patients with chest pain, based on data
collected with CLEOS; and
4. will evaluate economic aspects of routine care, as compared with management by CLEOS by
using standard health economy procedures and analyses to determine the resource
utilization and cost differences between management according to guidelines, based on
data collected with CLEOS, and current clinical practice.